Alkali metal distribution in composite cement pastes and its relation to accelerated ASR tests

Accelerated testing of alkali silica reaction (ASR) in concrete at elevated temperatures of 38 and 60 °C has an unknown impact on the alkali metal distribution in the cement paste. This paper investigates how the alkali metals released from hydrating Portland cement, limestone, and SCMs distribute between non-reactive and unreacted phases, C-A-S-H, and the pore solution. The SCMs investigated were fly ash and a volcanic pozzolan. The hydrate assemblage and pore solution of cement pastes cured at 20, 38 and 60 °C were analysed and related to the expansion of concrete prisms. There is little difference in alkali metal distribution at 20 and 38 °C, whereas curing at 60 °C has a large impact for the SCM containing blends. At alkali metal concentrations in the pore solution below 0.5 mol/L (Na + K) expansion of concrete was suppressed. Pore solution analysis could be used to screen new SCMs for ASR mitigation.publishedVersio

A functional spleen contributes to afucosylated IgG in humans

As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses. In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens. During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region. These glycans are essential for mediating the induction of immune effector functions. Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis. To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography–mass spectrometry (LC–MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis. IgG-Fc fucosylation was consistently increased after splenectomy, while no effects for IgG-Fc galactosylation and sialylation were observed. An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses. Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls. Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells

FMAP: Distributed Cooperative Multi-Agent Planning

This paper proposes FMAP (Forward Multi-Agent Planning), a fully-distributed multi-agent planning method that integrates planning and coordination. Although FMAP is specifically aimed at solving problems that require cooperation among agents, the flexibility of the domain-independent planning model allows FMAP to tackle multi-agent planning tasks of any type. In FMAP, agents jointly explore the plan space by building up refinement plans through a complete and flexible forward-chaining partial-order planner. The search is guided by h D T G , a novel heuristic function that is based on the concepts of Domain Transition Graph and frontier state and is optimized to evaluate plans in distributed environments. Agents in FMAP apply an advanced privacy model that allows them to adequately keep private information while communicating only the data of the refinement plans that is relevant to each of the participating agents. Experimental results show that FMAP is a general-purpose approach that efficiently solves tightly-coupled domains that have specialized agents and cooperative goals as well as loosely-coupled problems. Specifically, the empirical evaluation shows that FMAP outperforms current MAP systems at solving complex planning tasks that are adapted from the International Planning Competition benchmarks.This work has been partly supported by the Spanish MICINN under projects Consolider Ingenio 2010 CSD2007-00022 and TIN2011-27652-C03-01, the Valencian Prometeo project II/2013/019, and the FPI-UPV scholarship granted to the first author by the Universitat Politecnica de Valencia.Torreño Lerma, A.; Onaindia De La Rivaherrera, E.; Sapena Vercher, O. (2014). FMAP: Distributed Cooperative Multi-Agent Planning. Applied Intelligence. 41(2):606-626. https://doi.org/10.1007/s10489-014-0540-2S606626412Benton J, Coles A, Coles A (2012) Temporal planning with preferences and time-dependent continuous costs. In: Proceedings of the 22nd international conference on automated planning and scheduling (ICAPS). AAAI, pp 2–10Borrajo D. (2013) Multi-agent planning by plan reuse. In: Proceedings of the 12th international conference on autonomous agents and multi-agent systems (AAMAS). IFAAMAS, pp 1141–1142Boutilier C, Brafman R (2001) Partial-order planning with concurrent interacting actions. J Artif Intell Res 14(105):136Brafman R, Domshlak C (2008) From one to many: planning for loosely coupled multi-agent systems. In: Proceedings of the 18th international conference on automated planning and scheduling (ICAPS). AAAI, pp 28–35Brenner M, Nebel B (2009) Continual planning and acting in dynamic multiagent environments. J Auton Agents Multiagent Syst 19(3):297–331Bresina J, Dearden R, Meuleau N, Ramakrishnan S, Smith D, Washington R (2002) Planning under continuous time and resource uncertainty: a challenge for AI. In: Proceedings of the 18th conference on uncertainty in artificial intelligence (UAI). Morgan Kaufmann, pp 77–84Cox J, Durfee E (2009) Efficient and distributable methods for solving the multiagent plan coordination problem. Multiagent Grid Syst 5(4):373–408Crosby M, Rovatsos M, Petrick R (2013) Automated agent decomposition for classical planning. In: Proceedings of the 23rd international conference on automated planning and scheduling (ICAPS). AAAI, pp 46–54Dimopoulos Y, Hashmi MA, Moraitis P (2012) μ-satplan: Multi-agent planning as satisfiability. Knowl-Based Syst 29:54–62Fikes R, Nilsson N (1971) STRIPS: a new approach to the application of theorem proving to problem solving. Artif Intell 2(3):189–208Gerevini A, Haslum P, Long D, Saetti A, Dimopoulos Y (2009) Deterministic planning in the fifth international planning competition: PDDL3 and experimental evaluation of the planners. Artif Intell 173(5-6):619–668Ghallab M, Nau D, Traverso P (2004) Automated planning. Theory and practice. Morgan KaufmannGünay A, Yolum P (2013) Constraint satisfaction as a tool for modeling and checking feasibility of multiagent commitments. Appl Intell 39(3):489–509Helmert M (2004) A planning heuristic based on causal graph analysis. In: Proceedings of the 14th international conference on automated planning and scheduling ICAPS. AAAI, pp 161–170Hoffmann J, Nebel B (2001) The FF planning system: fast planning generation through heuristic search. J Artif Intell Res 14:253–302Jannach D, Zanker M (2013) Modeling and solving distributed configuration problems: a CSP-based approach. IEEE Trans Knowl Data Eng 25(3):603–618Jonsson A, Rovatsos M (2011) Scaling up multiagent planning: a best-response approach. In: Proceedings of the 21st international conference on automated planning and scheduling (ICAPS). AAAI, pp 114–121Kala R, Warwick K (2014) Dynamic distributed lanes: motion planning for multiple autonomous vehicles. Appl Intell:1–22Koehler J, Ottiger D (2002) An AI-based approach to destination control in elevators. AI Mag 23(3):59–78Kovacs DL (2011) Complete BNF description of PDDL3.1. Technical reportvan der Krogt R (2009) Quantifying privacy in multiagent planning. Multiagent Grid Syst 5(4):451–469Kvarnström J (2011) Planning for loosely coupled agents using partial order forward-chaining. In: Proceedings of the 21st international conference on automated planning and scheduling (ICAPS). AAAI, pp 138–145Lesser V, Decker K, Wagner T, Carver N, Garvey A, Horling B, Neiman D, Podorozhny R, Prasad M, Raja A et al (2004) Evolution of the GPGP/TAEMS domain-independent coordination framework. Auton Agents Multi-Agent Syst 9(1–2):87–143Long D, Fox M (2003) The 3rd international planning competition: results and analysis. J Artif Intell Res 20:1–59Nissim R, Brafman R, Domshlak C (2010) A general, fully distributed multi-agent planning algorithm. In: Proceedings of the 9th international conference on autonomous agents and multiagent systems (AAMAS). IFAAMAS, pp 1323–1330O’Brien P, Nicol R (1998) FIPA - towards a standard for software agents. BT Tech J 16(3):51–59Öztürk P, Rossland K, Gundersen O (2010) A multiagent framework for coordinated parallel problem solving. Appl Intell 33(2):132–143Pal A, Tiwari R, Shukla A (2013) Communication constraints multi-agent territory exploration task. Appl Intell 38(3):357–383Richter S, Westphal M (2010) The LAMA planner: guiding cost-based anytime planning with landmarks. J Artif Intell Res 39(1):127–177de la Rosa T, García-Olaya A, Borrajo D (2013) A case-based approach to heuristic planning. Appl Intell 39(1):184–201Sapena O, Onaindia E (2008) Planning in highly dynamic environments: an anytime approach for planning under time constraints. Appl Intell 29(1):90–109Sapena O, Onaindia E, Garrido A, Arangú M (2008) A distributed CSP approach for collaborative planning systems. Eng Appl Artif Intell 21(5):698–709Serrano E, Such J, Botía J, García-Fornes A (2013) Strategies for avoiding preference profiling in agent-based e-commerce environments. Appl Intell:1–16Smith D, Frank J, Jónsson A (2000) Bridging the gap between planning and scheduling. Knowl Eng Rev 15(1):47–83Such J, García-Fornes A, Espinosa A, Bellver J (2012) Magentix2: a privacy-enhancing agent platform. Eng Appl Artif Intell:96–109Tonino H, Bos A, de Weerdt M, Witteveen C (2002) Plan coordination by revision in collective agent based systems. Artif Intell 142(2):121–145Torreño A, Onaindia E, Sapena O (2012) An approach to multi-agent planning with incomplete information. In: Proceedings of the 20th European conference on artificial intelligence (ECAI), vol 242. IOS Press, pp 762–767Torreño A, Onaindia E, Sapena O (2014) A flexible coupling approach to multi-agent planning under incomplete information. Knowl Inf Syst 38(1):141–178Van Der Krogt R, De Weerdt M (2005) Plan repair as an extension of planning. In: Proceedings of the 15th international conference on automated planning and scheduling (ICAPS). AAAI, pp 161–170de Weerdt M, Clement B (2009) Introduction to planning in multiagent systems. Multiagent Grid Syst 5(4):345– 355Yokoo M, Durfee E, Ishida T, Kuwabara K (1998) The distributed constraint satisfaction problem: formalization and algorithms. IEEE Trans Knowl Data Eng 10(5):673–685Zhang J, Nguyen X, Kowalczyk R (2007) Graph-based multi-agent replanning algorithm. In: Proceedings of the 6th international joint conference conference on autonomous agents and multiagent systems (AAMAS). IFAAMAS, pp 798–80

A functional spleen contributes to afucosylated IgG in humans

As a lymphoid organ, the spleen hosts a wide range of immune cell populations, which not only remove blood-borne antigens, but also generate and regulate antigen-specific immune responses. In particular, the splenic microenvironment has been demonstrated to play a prominent role in adaptive immune responses to enveloped viral infections and alloantigens. During both types of immunizations, antigen-specific immunoglobulins G (IgGs) have been characterized by the reduced amount of fucose present on N-linked glycans of the fragment crystallizable (Fc) region. These glycans are essential for mediating the induction of immune effector functions. Therefore, we hypothesized that a spleen may modulate humoral responses and serve as a preferential site for afucosylated IgG responses, which potentially play a role in immune thrombocytopenia (ITP) pathogenesis. To determine the role of the spleen in IgG-Fc glycosylation, we performed IgG subclass-specific liquid chromatography-mass spectrometry (LC-MS) analysis of Fc glycosylation in a large cohort of individuals splenectomized due to trauma, due to ITP, or spherocytosis. IgG-Fc fucosylation was consistently increased after splenectomy, while no effects for IgG-Fc galactosylation and sialylation were observed. An increase in IgG1- and IgG2/3-Fc fucosylation level upon splenectomy has been reported here for the first time, suggesting that immune responses occurring in the spleen may be particularly prone to generate afucosylated IgG responses. Surprisingly, the level of total IgG-Fc fucosylation was decreased in ITP patients compared to healthy controls. Overall, our results suggest a yet unrecognized role of the spleen in either the induction or maintenance of afucosylated IgG responses by B cells.Proteomic

Phylogenetic Relationships of the Marine Haplosclerida (Phylum Porifera) Employing Ribosomal (28S rRNA) and Mitochondrial (cox1, nad1) Gene Sequence Data

The systematics of the poriferan Order Haplosclerida (Class Demospongiae) has been under scrutiny for a number of years without resolution. Molecular data suggests that the order needs revision at all taxonomic levels. Here, we provide a comprehensive view of the phylogenetic relationships of the marine Haplosclerida using many species from across the order, and three gene regions. Gene trees generated using 28S rRNA, nad1 and cox1 gene data, under maximum likelihood and Bayesian approaches, are highly congruent and suggest the presence of four clades. Clade A is comprised primarily of species of Haliclona and Callyspongia, and clade B is comprised of H. simulans and H. vansoesti (Family Chalinidae), Amphimedon queenslandica (Family Niphatidae) and Tabulocalyx (Family Phloeodictyidae), Clade C is comprised primarily of members of the Families Petrosiidae and Niphatidae, while Clade D is comprised of Aka species. The polyphletic nature of the suborders, families and genera described in other studies is also found here

Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial

Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib. Induction consisted of three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT. Patients responding were randomised between bortezomib maintenance (1·3 mg/m2 intravenously once every 2 weeks, for 2 years) and observation. Of 135 eligible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised. With a median follow-up of 77·5 months for patients still alive, 5-year event-free survival (EFS) was 51% (95% CI 42–59%); 5-year overall survival (OS) was 73% (95% CI 65–80%). The median follow-up of randomised patients still alive was 71·5 months. Patients with bortezomib maintenance had a 5-year EFS of 63% (95% CI 44–78%) and 5-year OS of 90% (95% CI 72–97%). The patients randomised to observation had 5-year PFS of 60% (95% CI, 40–75%) and OS of 90% (95% CI 72–97%). In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT

Risk Stratification in Older Intensively Treated Patients With AML

\ua9 2024 by American Society of Clinical Oncology.PURPOSE AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive chemotherapy followed by allogeneic hematopoietic cell transplantation (allo-HCT). Thus, there is an urgent need in clinical practice for a prognostic model to identify older patients with AML who benefit from curative treatment. METHODS We studied 1,910 intensively treated patients older than 60 years with AML and high-risk myelodysplastic syndrome (HR-MDS) from two cohorts (NCRIAML18 and HOVON-SAKK). The median patient age was 67 years. Using a random survival forest, clinical, molecular, and cytogenetic variables were evaluated in an AML development cohort (n = 1,204) for association with overall survival (OS). Relative weights of selected variables determined the prognostic model, which was validated in AML (n = 491) and HR-MDS cohorts (n = 215). RESULTS The complete cohort had a high frequency of poor-risk features, including 2022 European LeukemiaNet adverse-risk (57.3%), mutated TP53 (14.4%), and myelodysplasia-related genetic features (65.1%). Nine variables were used to construct four groups with highly distinct 4-year OS in the (1) AML development, (2) AML validation, and (3) HR-MDS test cohorts ([1] favorable: 54% \ub1 4%, intermediate: 38% \ub1 2%, poor: 21% \ub1 2%, very poor: 4% \ub1 1%; [2] 54% \ub1 9%, 43% \ub1 4%, 27% \ub1 4%, 4% \ub1 3%; and [3] 54% \ub1 10%, 33% \ub1 6%, 14% \ub1 5%, 0% \ub1 3%, respectively). This new AML60+ classification improves current prognostic classifications. Importantly, patients within the AML60+ intermediate- and very poor-risk group significantly benefited from allo-HCT, whereas the poor-risk patients showed an indication, albeit nonsignificant, for improved outcome after allo-HCT. CONCLUSION The new AML60+ classification provides prognostic information for intensively treated patients 60 years and older with AML and HR-MDS and identifies patients who benefit from intensive chemotherapy and allo-HCT

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes:the HOVON89 trial

A randomized phase-II study was performed in low/int-1 risk MDS (IPSS) to study efficacy and safety of lenalidomide without (arm A) or with (arm B) ESA/G-CSF. In arm B, patients without erythroid response (HI-E) after 4 cycles received ESA; G-CSF was added if no HI-E was obtained by cycle 9. HI-E served as primary endpoint. Flow cytometry and next-generation sequencing were performed to identify predictors of response. The final evaluation comprised 184 patients; 84% non-del(5q), 16% isolated del(5q); median follow-up: 70.7 months. In arm A and B, 39 and 41% of patients achieved HI-E; median time-to-HI-E: 3.2 months for both arms, median duration of-HI-E: 9.8 months. HI-E was significantly lower in non-del(5q) vs. del(5q): 32% vs. 80%. The same accounted for transfusion independency-at-week 24 (16% vs. 67%), but similar in both arms. Apart from presence of del(5q), high percentages of bone marrow lymphocytes and progenitor B-cells, a low number of mutations, absence of ring sideroblasts, and SF3B1 mutations predicted HI-E. In conclusion, lenalidomide induced HI-E in patients with non-del(5q) and del(5q) MDS without additional effect of ESA/G-CSF. The identified predictors of response may guide application of lenalidomide in lower-risk MDS in the era of precision medicine. (EudraCT 2008-002195-10).</p

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels are reported. Induction therapy consisted of four cycles of carfilzomib 20/27 mg/m2 (n=50), 20/36 mg/m2 (n=20), 20/45 mg/m2 (n=21), and 20/56 mg/m2 (n=20) on days 1, 2, 8, 9, 15, 16 of a 28-day cycle; thalidomide 200 mg on day 1 through 28 and dexamethasone 40 mg weekly. Induction therapy was followed by high-dose melphalan and autologous stem cell transplantation and consolidation therapy with four cycles of carfilzomib, thalidomide and dexamethasone in the same schedule except a lower dose of thalidomide (50 mg). Very good partial response rate or better and complete response rate or better after ind

Process Mining for Six Sigma

Process mining offers a set of techniques for gaining data-based insights into business processes from event logs. The literature acknowledges the potential benefits of using process mining techniques in Six Sigma-based process improvement initiatives. However, a guideline that is explicitly dedicated on how process mining can be systematically used in Six Sigma initiatives is lacking. To address this gap, the Process Mining for Six Sigma (PMSS) guideline has been developed to support organizations in systematically using process mining techniques aligned with the DMAIC (Define-Measure-Analyze-Improve-Control) model of Six Sigma. Following a design science research methodology, PMSS and its tool support have been developed iteratively in close collaboration with experts in Six Sigma and process mining, and evaluated by means of focus groups, demonstrations and interviews with industry experts. The results of the evaluations indicate that PMSS is useful as a guideline to support Six Sigma-based process improvement activities. It offers a structured guideline for practitioners by extending the DMAIC-based standard operating procedure. PMSS can help increasing the efficiency and effectiveness of Six Sigma-based process improving efforts. This work extends the body of knowledge in the fields of process mining and Six Sigma, and helps closing the gap between them. Hence, it contributes to the broad field of quality management